Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9782940 | 0.89 | KMT2A (0.38) | POLBL3MBTL1KMT2AKDM4EMAPT | |
| SCHEMBL17820014 | 0.83 | POLB (0.50) | POLBL3MBTL1KMT2AKDM4EHPGD | |
| SCHEMBL15751480 | 0.82 | POLB (0.49) | POLBL3MBTL1KMT2AKDM4EHPGD | |
| SCHEMBL7170956 | 0.81 | KDM4E (0.44) | L3MBTL1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL17820325 | 0.79 | POLB (0.46) | POLBL3MBTL1KMT2AKDM4EHPGD | |
| SCHEMBL14684052 | 0.79 | POLB (0.46) | POLBL3MBTL1KMT2AKDM4EHPGD | |
| SCHEMBL3405646 | 0.78 | POLB (0.50) | POLBL3MBTL1KMT2AKDM4EHPGD | |
| SCHEMBL7493215 | 0.78 | POLB (0.52) | POLBL3MBTL1KMT2AKDM4EHPGD | |
| SCHEMBL2643085 | 0.78 | TDP1 (0.48) | L3MBTL1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL26677090 | 0.78 | SIRT6 (0.57) | L3MBTL1KMT2AKDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8865720-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| CN-103797000-A | Amidine compound or salt thereof | TAISHO PHARMACEUTICAL CO LTD | 2014-05-14 | — | — | CN | disclosed |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-06 | — | — | US | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| CN-103476768-A | 6, 5-heterocyclic propargyl alcohol compounds and uses thereof | HOFFMANN LA ROCHE | 2013-12-25 | — | — | CN | disclosed |
| US-8557825-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20120088754-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF VAN (BE) | 2012-04-12 | — | — | US | disclosed |
| US-8101567-B2 | Heteroaryl-containing tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8097611-B2 | Sulfonyl-derivatives as novel or histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-01-17 | — | — | US | disclosed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| US-20110177612-A1 | Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders | ARENA PHARMACEUTICALS, INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20090202485-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| CN-1980912-A | Pyrazole derivatives | DAIICHI SEIYAKU CO (JP) | 2007-06-13 | — | — | CN | disclosed |
| CN-1902191-A | Amidopyrazole derivative | DAIICHI SEIYAKU CO (JP) | 2007-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088754-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | POLB 3582/4885L3MBTL1 1102/4885KMT2A 28/4885 |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | POLB 3582/4885L3MBTL1 1102/4885KMT2A 28/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | POLB 3667/4885L3MBTL1 1941/4885KMT2A 480/4885 |
| US-20090202485-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | PRSS1, CTSC, SPINT2 | POLB 4052/4885L3MBTL1 2087/4885KMT2A 2661/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | POLB 1083/4885L3MBTL1 2918/4885KMT2A 87/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | POLB 1787/4885L3MBTL1 1789/4885KMT2A 4192/4885 |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | CTSC, PRSS1, SPINT2 | POLB 3584/4885L3MBTL1 2664/4885KMT2A 2768/4885 |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | POLB 3293/4885L3MBTL1 3374/4885KMT2A 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.